Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dabrafenib Mesylate

FDA-approved product (capsule, oral), marketed as Tafinlar.

Registered studies
24
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dabrafenib Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cutaneous melanoma
  • Glioma
  • Melanoma
  • Metastatic melanoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
B-raf serine-threonine kinase (braf) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dabrafenib Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dabrafenib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

    NCT07110246 · start 2025-11-07

    Registered record
    Registry ID
    NCT07110246
    Conditions
    BRAF V600 Mutation; Low-grade Glioma; Low Grade Glioma of Brain; Recurrent Low Grade Glioma
    Interventions
    Dabrafenib; Trametinib; Magnetic Resonance Imaging (MRI); Specimen Collection; Optional Lumbar puncture
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-07
    Completion
    2032-03-31
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBRAF V600 Mutation; Low-grade Glioma; Low Grade Glioma of Brain; Recurrent Low Grade Glioma
    InterventionDabrafenib; Trametinib; Magnetic Resonance Imaging (MRI); Specimen Collection +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Precision Cancer Therapy in Rare Cancers

    NCT06119789 · start 2025-03-20

    Registered record
    Registry ID
    NCT06119789
    Conditions
    Rare Malignant Neoplasm
    Interventions
    Imatinib; Trametinib; Dabrafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-20
    Completion
    2036-08-01
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRare Malignant Neoplasm
    InterventionImatinib; Trametinib; Dabrafenib
    PhasePhase 2
    Registry statusRecruiting

  • Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

    NCT06264778 · start 2024-03-01

    Registered record
    Registry ID
    NCT06264778
    Conditions
    Ameloblastoma
    Interventions
    Dabrafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-03-01
    Completion
    2025-12-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmeloblastoma
    InterventionDabrafenib
    PhasePhase 3
    Registry statusUnknown

  • Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

    NCT04557956 · start 2021-08-19

    Registered record
    Registry ID
    NCT04557956
    Conditions
    Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma
    Interventions
    Biopsy Procedure; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Tazemetostat Hydrobromide; Trametinib Dimethyl Sulfoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2021-08-19
    Completion
    2027-03-11
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma
    InterventionBiopsy Procedure; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test +4 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

    NCT04527549 · start 2021-06-01

    Registered record
    Registry ID
    NCT04527549
    Conditions
    Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma
    Interventions
    Dabrafenib mesylate; Hydroxychloroquine; Placebo Administration; Trametinib dimethyl sulfoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-06-01
    Completion
    2024-01-08
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8 +1 more
    InterventionDabrafenib mesylate; Hydroxychloroquine; Placebo Administration; Trametinib dimethyl sulfoxide
    PhasePhase 2
    Registry statusTerminated

  • Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

    NCT03878524 · start 2020-04-01

    Registered record
    Registry ID
    NCT03878524
    Conditions
    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous
    Interventions
    Abemaciclib; Abiraterone; Afatinib; Bevacizumab; Bicalutamide; Biospecimen Collection; Bortezomib; Cabazitaxel; Cabozantinib; Capecitabine; Carboplatin; Celecoxib; Cobimetinib; Copanlisib; Dabrafenib; Dacomitinib; Darolutamide; Dasatinib; Doxorubicin; Durvalumab; Enasidenib; Entrectinib; Enzalutamide; Erlotinib; Everolimus; Fluorouracil; Idelalisib; Imatinib; Ipilimumab; Lenvatinib; Leucovorin; Lorlatinib; Losartan; Nab-paclitaxel; Neratinib; Nivolumab; Olaparib; Oxaliplatin; Palbociclib; Panobinostat; Pembrolizumab; Pertuzumab; Ponatinib; Quality-of-Life Assessment; Regorafenib; Ruxolitinib; Sirolimus; Sorafenib; Sunitinib; Trametinib; Trastuzumab Emtansine; Tretinoin; Vemurafenib; Venetoclax; Vismodegib; Vorinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-04-01
    Completion
    2020-12-10
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma +19 more
    InterventionAbemaciclib; Abiraterone; Afatinib; Bevacizumab +52 more
    PhasePhase 1
    Registry statusTerminated

  • Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

    NCT03919071 · start 2020-02-20

    Registered record
    Registry ID
    NCT03919071
    Conditions
    Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma; Glioblastoma; Malignant Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma
    Interventions
    Biospecimen Collection; Dabrafenib Mesylate; Lumbar Puncture; Magnetic Resonance Imaging; Radiation Therapy; Trametinib Dimethyl Sulfoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-02-20
    Completion
    2027-09-30
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma +4 more
    InterventionBiospecimen Collection; Dabrafenib Mesylate; Lumbar Puncture; Magnetic Resonance Imaging +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

    NCT04201457 · start 2020-01-17

    Registered record
    Registry ID
    NCT04201457
    Conditions
    Low Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1
    Interventions
    Dabrafenib; Trametinib; Hydroxychloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2020-01-17
    Completion
    2026-12-31
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1
    InterventionDabrafenib; Trametinib; Hydroxychloroquine
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

    NCT03794297 · start 2019-01-04

    Registered record
    Registry ID
    NCT03794297
    Conditions
    Erdheim-Chester Disease
    Interventions
    Dabrafenib Mesylate; Quality-of-Life Assessment; Questionnaire Administration; Trametinib Dimethyl Sulfoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-01-04
    Completion
    2021-02-18
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErdheim-Chester Disease
    InterventionDabrafenib Mesylate; Quality-of-Life Assessment; Questionnaire Administration; Trametinib Dimethyl Sulfoxide
    PhasePhase 2
    Registry statusWithdrawn

  • Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

    NCT02447939 · start 2017-05

    Registered record
    Registry ID
    NCT02447939
    Conditions
    Melanoma
    Interventions
    Dabrafenib; Trametinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2017-05
    Completion
    2018-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionDabrafenib; Trametinib
    PhasePhase 1
    Registry statusWithdrawn

  • Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

    NCT04439292 · start 2016-01-04

    Registered record
    Registry ID
    NCT04439292
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
    Interventions
    Dabrafenib Mesylate; Trametinib Dimethyl Sulfoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-01-04
    Completion
    2026-12-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma +2 more
    InterventionDabrafenib Mesylate; Trametinib Dimethyl Sulfoxide
    PhasePhase 2
    Registry statusActive not recruiting

  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

    NCT02224781 · start 2015-09-08

    Registered record
    Registry ID
    NCT02224781
    Conditions
    Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma
    Interventions
    Biospecimen Collection; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test; Ipilimumab; Multigated Acquisition Scan; Nivolumab; Quality-of-Life Assessment; Trametinib Dimethyl Sulfoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2015-09-08
    Completion
    2026-12-19
    Enrolment
    267

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma +1 more
    InterventionBiospecimen Collection; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test +5 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

    NCT02281760 · start 2014-11-01

    Registered record
    Registry ID
    NCT02281760
    Conditions
    BRAF V600E Mutation
    Interventions
    Dabrafenib Mesylate; Trametinib Dimethyl Sulfoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-11-01
    Completion
    2018-08-29
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBRAF V600E Mutation
    InterventionDabrafenib Mesylate; Trametinib Dimethyl Sulfoxide
    PhasePhase 2
    Registry statusCompleted

  • Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

    NCT02196181 · start 2014-09-19

    Registered record
    Registry ID
    NCT02196181
    Conditions
    Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
    Interventions
    Biospecimen Collection; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test; Multigated Acquisition Scan; Positron Emission Tomography; Trametinib Dimethyl Sulfoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2014-09-19
    Completion
    2027-03-15
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
    InterventionBiospecimen Collection; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test +3 more
    PhasePhase 2
    Registry statusActive not recruiting